Sentry Investment Management LLC lifted its stake in shares of Icon Plc (NASDAQ:ICLR) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,807 shares of the medical research company’s stock after purchasing an additional 763 shares during the period. Sentry Investment Management LLC’s holdings in Icon were worth $4,240,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. GRATRY & Co LLC raised its position in shares of Icon by 5.1% during the third quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock worth $3,433,000 after purchasing an additional 1,474 shares during the period. Insight Capital Research & Management Inc. acquired a new stake in shares of Icon during the third quarter worth $1,359,000. BT Investment Management Ltd acquired a new stake in shares of Icon during the third quarter worth $325,000. JPMorgan Chase & Co. raised its position in shares of Icon by 11.5% during the third quarter. JPMorgan Chase & Co. now owns 42,043 shares of the medical research company’s stock worth $4,697,000 after purchasing an additional 4,320 shares during the period. Finally, NorthCoast Asset Management LLC raised its position in shares of Icon by 23.4% during the third quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 3,419 shares during the period. 89.66% of the stock is currently owned by institutional investors.

Icon Plc (ICLR) opened at $107.02 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a 52-week low of $76.46 and a 52-week high of $124.48. The firm has a market capitalization of $5,795.35, a price-to-earnings ratio of 20.74, a P/E/G ratio of 1.51 and a beta of 0.48.

ICLR has been the topic of several recent analyst reports. Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $132.00 price target on the stock in a research report on Tuesday, January 9th. KeyCorp reissued a “buy” rating and set a $130.00 price target on shares of Icon in a research report on Thursday, January 11th. ValuEngine raised Icon from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. SunTrust Banks reissued a “buy” rating and set a $138.00 price target on shares of Icon in a research report on Sunday, October 29th. Finally, Barclays upped their price target on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Icon currently has a consensus rating of “Buy” and an average price target of $124.55.

WARNING: This news story was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/02/12/icon-plc-iclr-stake-raised-by-sentry-investment-management-llc.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.